Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
434 results about "Mitosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In cell biology, mitosis (/maɪˈtoʊsɪs/) is a part of the cell cycle when replicated chromosomes are separated into two new nuclei. Cell division gives rise to genetically identical cells in which the number of chromosomes is maintained. In general, mitosis (division of the nucleus) is preceded by the S stage of interphase (during which the DNA is replicated) and is often accompanied or followed by cytokinesis, which divides the cytoplasm, organelles and cell membrane into two new cells containing roughly equal shares of these cellular components. Mitosis and cytokinesis together define the mitotic (M) phase of an animal cell cycle—the division of the mother cell into two daughter cells genetically identical to each other.
RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
InactiveUS20050239731A1Improve bioavailabilityMinimize the possibilityBiocideSugar derivativesMAP Kinase GeneMitogen-activated protein
This invention relates to compounds, compositions, and methods useful for modulating mitogen activated protein kinase (MAP kinase) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MAP kinase gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of MAP kinase genes, such as Jun amino-terminal kinase (e.g., JNK-1, JNK-2), p38 (MAPK 14), ERK (e.g., ERK-1, ERK-2) and / or c-Jun.
Owner:SIRNA THERAPEUTICS INC
Isolation, cultivation and uses of stem/progenitor cells
The present invention relates to a method for isolating stem / progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem / progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and / or mesenchymal stem / progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem / progenitor cells into epithelial and / or mesenchymal cells.
Owner:CELLRESEARCH CORP PTE LTD
Cancer treatments
InactiveUS20060128777A1Promoting bendamustine useReduce spreadOrganic active ingredientsBiocideTreatment effectCancer therapy
Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such treatments are also provided.
Owner:CEPHALON INC
Automated segmentation, classification, and tracking of cell nuclei in time-lapse microscopy
InactiveUS20060127881A1Efficient dynamic cell imaging studyIncrease capacityImage enhancementImage analysisAutomated segmentationInterphase Cell
Methods and apparatus are provided for the automated analysis of images of living cells acquired by time-lapse microscopy. The new methods and apparatus can be used for the segmentation, classification and tracking of individual cells in a cell population, and for the extraction of biologically significant features from the cell images. Based upon certain extracted features, the inventive image analysis methods can characterize a cell as mitotic or interphase and / or can classify a cell into one of the following mitotic phases: prophase, metaphase, arrested metaphase, and anaphase with high accuracy.
Owner:THE BRIGHAM & WOMENS HOSPITAL INC
Reducing Motility of Cancer Cells Using Tumor Treating Fields (TTFields)
ActiveUS20170281934A1Reduce exerciseAvoid spreadingOrganic active ingredientsElectrotherapyCancer cellMotility
The spreading of cancer cells in a target region can be inhibited by imposing a first AC electric field in the target region for a first interval of time, with a frequency and amplitude selected to disrupt mitosis of the cancer cells; and imposing a second AC electric field in the target region for a second interval of time, with a frequency and the amplitude selected to reduce motility of the cancer cells. The amplitude of the second AC electric field is lower than the amplitude of the first AC electric field.
Owner:NOVOCURE GMBH
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
ActiveUS20100303811A1Increase heightVirusesPeptide/protein ingredientsIMMUNE SUPPRESSANTSAutoimmune responses
The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF / TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.
Owner:OCHI ATSUO
Kinesin inhibitors
The present invention provides for compounds, compositions, methods and systems for inhibiting cell growth. More specifically, the present invention provides for methods, compounds and compositions which are capable of inhibiting mitosis in metabolically active cells. Compounds, compositions and methods of the present invention inhibit the activity of a protein involved in the assembly and maintenance of the mitotic spindle. One class of proteins which acts on the mitotic spindle is the family of mitotic kinesins, a subset of the kinesin superfamily.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Classifying cells based on information contained in cell images
InactiveUS6876760B1Accurate classificationImage enhancementImage analysisImaging analysisPhases of clinical research
Image analysis methods analyze images of cells and place the cells in particular cell cycle phases based upon certain features extracted from the images. The methods can also quantify the total amount of DNA in a cell based on specific features such as fluorescence intensity from fluorescent molecules that bind to DNA. Further, the methods can characterize a cell as mitotic or interphase based on chosen parameters such as the variance in intensity observed in a cell image and / or the size of a region containing DNA. In one example, image analysis methods can classify the cell into one of the following five phases: G1, S, G2, telophase, and an early stage mitotic phase comprised of prophase, metaphase, and anaphase.
Owner:CYTOKINETICS INC
Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
InactiveUS20030202973A1Reduce HAMA responseMinimize side effectsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHuman tumorHuman epidermal growth factor receptor
A method of inhibiting the growth of refractory tumors that are stimulated by mitogenic ligands of epidermal growth factor receptor in human patients, comprising treating the human patients with an effective amount of a mitogenic ligand antagonist.
Owner:DR GEORGE PIECZENIK
Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
InactiveUS20070122882A1Efficient separationEasy to prepareFungiBacteriaNeuro-degenerative diseaseNovel gene
A novel gene 65B13 expressed specifically and transiently in dopaminergic neuron precursor cells immediately after cell cycle exit was obtained by the present invention. The cellular expression of 65B13 can be used as an index to select cells that are suitable in terms of their safety, survival rate, and network formation ability, for transplant therapy of neurodegenerative diseases such as Parkinson's disease.
Owner:EISIA R&D MANAGEMENT CO LTD
Cancer Metastasis Inhibitor
InactiveUS20120183539A1Promoted angiogenesisPromoted tumor growthImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHematopoietic cellLymphatic Spread
The present inventors used a model of intrasplenically induced liver metastasis to determine whether or not NF-κB activation in the liver is involved in the onset of metastatic tumors. When IKKβ was deleted from both liver cells and hematopoietically-derived cells, the onset of tumors was reduced remarkably. Tumor cells activated neighboring bone marrow cells (Kupffer cells) and produced mitogens such as interleukin (IL)-6, and this promoted angiogenesis and growth of tumors. The mitogen production depended on NF-κB in hematopoietically-derived Kupffer cells. Furthermore, treatment with an anti-IL-6 receptor antibody decreased the degree of metastatic tumor development. That is, the present inventors showed that tumor metastasis depends on inflammation, and proinflammatory intervention that targets Kupffer cells is useful for chemical prevention of metastatic tumors. Furthermore, it was shown that inhibition of the IKKβ / NF-κB signal transduction pathway, in particular IL-6 inhibition, can be utilized for anti-metastasis agents.
Owner:MAEDA CORPORATION
Culture medium for epithelial stem cells and organoids comprising said stem cells
ActiveUS20120028355A1Profound effectGastrointestinal cellsMetabolism disorderCell culture mediaAdenoma
The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids and pancreatic organoids that are formed in the culture medium.
Owner:KONINK NEDERLANDSE AKADE VAN WETENSCHAPPEN
Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
InactiveUS20050187150A1Promotes dimerizationTreat and ameliorate disorderCompound screeningApoptosis detectionTernary complexFGF Receptor
The present invention provides methods and compositions for modulating FGF-signaling and activities associated therewith, such as mitogenesis and angiogenesis. In particular, the invention provides crystal structure coordinates for a ternary complex of an FGF receptor, and FGF ligand, and a third compound, sucrose octasulfate, that binds to the FGF receptor and ligand to promote formation and dimerization of the ternary complex. Screening methods are provided by which novel agonists and antagonist for FGF-mediating signaling and activities may be identified using these crystal structure coordinates. Exemplary compounds are also provided that have novel utilities as agonists or antagonists of FGF-mediated signaling and activites.
Owner:NEW YORK UNIV +1
Paraffin section method for fern gametophytes
InactiveCN102607907AAvoid poor resultsGood slice methodPreparing sample for investigationParaffin waxMicroscopic exam
The invention discloses a paraffin section method for fern gametophytes, which comprises the steps of material selection and fixation, washing, coloration and bluing, dehydration and hyalinizing, waxing and embedding, sectioning, patching, dewaxing and mounting, as well as microscopic examination and photographing, wherein improved FAA (formalin, acetic acid and alcohol) stationary liquid is adopted in the fixation, and the stationary liquid consists of formalin, acetic acid and 30% alcohol (formalin:acetic acid:30% alcohol = 1:1:18). The method is adopted, so that the disadvantage of much youngness of the fern gametophytes can be effectively overcome; the fixation can be well performed for cell divisions at all stages; from a paraffin section in a later stage, a plurality of mitotic sections can be observed, so that a whole development process can be reflected detailedly; therefore, the method has high development and application values.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY
Mitotic kinesin inhibitors
The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP
Mitotic kinesin inhibitors
The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP
Anti-igf antibodies
ActiveUS20100150940A1Organic active ingredientsHeavy metal active ingredientsDiseaseInsulin receptor
Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
Owner:BOEHRINGER INGELHEIM INT GMBH
Culture medium for epithelial stem cells and organoids comprising the stem cells
The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids and pancreatic organoids that are formed in the culture medium.
Owner:KONINK NEDERLANDSE AKADE VAN WETENSCHAPPEN
Bone matrix compositions and methods
Owner:WARSAW ORTHOPEDIC INC
Yeast with increased butanol tolerance involving high osmolarity/glycerol response pathway
ActiveUS8455225B2Improve toleranceIncrease productionMicroorganismsTransferasesYeastIncreased tolerance
Increasing tolerance to butanol in yeast has been accomplished by increasing activity of the high osmolarity / glycerol response pathway. Yeast with increased expression of PBS2p, a mitogen activated protein kinase kinase of the MAPK module of the high osmolarity / glycerol response pathway may be used for improved butanol production.
Owner:GEVO INC
Yeast with increased butanol tolerance involving cell wall integrity pathway
Increasing tolerance to butanol in yeast has been accomplished by increasing activity of the cell wall integrity pathway. Yeast with increased expression of SLT2p, a mitogen activated protein kinase of the MAPK module of the cell wall integrity pathway had increased tolerance to isobutanol. These yeast may be used for improved butanol production.
Owner:GEVO INC
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
InactiveUS7060271B2Peptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsHuman typeReceptor activation
The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerization, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.
Owner:MILLENNIUM PHARMA INC
Mitotic kinesin inhibitors
The present invention relates to azaquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:COLEMAN PAUL +2
Compositions for elastrogenesis and connective tissue treatment
ActiveUS20050208150A1Increase elasticityGood lookingHeavy metal active ingredientsCosmetic preparationsArterial smooth muscle cellsFiber
The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.
Owner:HOSPITAL FOR SICK CHILDREN +1
Mitotic kinesin inhibitors
The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP
Culture medium for epithelial stem cells and organoids comprising the stem cells
Owner:KONINK NEDERLANDSE AKADE VAN WETENSCHAPPEN
Prodrugs of mitotic kinesin inhibitors
The present invention relates to phosphate ester prodrugs of dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP
Engineered human acidic fibroblast growth factors and associated methods
InactiveUS7790682B1Improve protein stabilityGreat mitogenic potencySugar derivativesPeptide/protein ingredientsWild typeAcidic Fibroblast Growth Factor
An engineered, purified polypeptide of acidic fibroblast growth factor (FGF-1) is described, the amino acid sequence of which consists essentially of SEQ ID NO: 1. The engineered polypeptide provides 70 times the mitogenic activity of wild type acidic fibroblast growth factor. Other engineered FGFs are also described, having altered properties, including reduced heparin binding affinity and increased mitogenicity as demonstrated with a model mammalian cell line derived from mice, NIH 3T3 fibroblasts.
Owner:FLORIDA STATE UNIV RES FOUND INC
Mitotic kinesin inhibitors and methods of use thereof
Owner:ARRAY BIOPHARMA
Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
The present invention relates to azolopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Owner:MERCK SHARP & DOHME CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com